%0 Journal Article
%A Kurte, Melina Sophie
%A Siefen, Ann-Cathrine
%A Jakobs, Florian
%A von Tresckow, Bastian
%A Reinhardt, Hans Christian
%A Kron, Florian
%T Cost-effectiveness analysis of transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma treatment options-Experience of the efficiency frontier approach.
%J European journal of haematology
%V 111
%N 6
%@ 0902-4441
%C Oxford
%I Wiley-Blackwell
%M DKFZ-2023-01756
%P 895-908
%D 2023
%Z 2023 Dec;111(6):895-908
%X The treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) changed remarkably since the European Medicines Agency-approved chimeric antigen receptor T-cell (CAR-T) therapies (axicabtagene ciloleucel [axi-cel], lisocabtagene maraleucel [liso-cel], tisagenlecleucel [tisa-cel]) for the third-line onwards (3+L), and targeted therapies (polatuzumab vedotin-bendamustine-rituximab [pola-BR], tafasitamab-lenalidomide [Tafa-L]) for the second-line (2L) onwards. As associated rising treatment costs represent an economic burden, the cost-effectiveness of transplant-ineligible R/R DLBCL interventions was assessed from a German healthcare payer's perspective, using the efficiency frontier (EF) approach.A systematic literature review was performed to determine the clinical benefit concerning median overall survival (OS) of bendamustine-rituximab (BR), rituximab-gemcitabine-oxaliplatin (R-GemOx), axi-cel, liso-cel, tisa-cel, pola-BR, and Tafa-L. First-year treatment costs (drug and medical services costs) were calculated. Results were merged on two-dimensional graphs illustrating 2L and 3+L EFs.Second-line EF is formed by BR (median OS 11.49 months, €23 958) and Tafa-L (45.7, €104 541), 3+L EF is formed by R-GemOx (12.0, €29 080), Tafa-L (15.5, €104 541), and axi-cel (18.69, €308 516). These interventions build the respective cost-effectiveness thresholds for novel interventions.Using the EF approach, the currently most cost-effective interventions (based on cost-effectiveness ratios) in the indication of R/R DLBCL were identified to guide international reimbursement decisions.
%K CAR-T-cell therapy (Other)
%K DLBCL (Other)
%K cost-effectiveness (Other)
%K diffuse large B-cell lymphoma (Other)
%K efficiency frontier (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37644352
%R 10.1111/ejh.14095
%U https://inrepo02.dkfz.de/record/282429